FLORHAM PARK, N.J., Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Celularity Inc. ( Nasdaq: CELU ) ( "Celularity" or the "Company" ) , a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, today announced that on August 21, 2025, Nasdaq notified the ...

FLORHAM PARK, N.J., July 09, 2025 ( GLOBE NEWSWIRE ) -- Celularity Inc. ( Nasdaq: CELU ) ( "Celularity" ) , a regenerative and cellular medicine company focused on addressing age-related and degenerative diseases, announced today that it entered into a strategic partnership with Fountain Life, a ...

Celularity retains financial and business advisor to provide outsourced accounting and consulting services during the transition period Celularity retains financial and business advisor to provide outsourced accounting and consulting services during the transition period ...

FLORHAM PARK, N.J., June 10, 2025 ( GLOBE NEWSWIRE ) -- Celularity Inc. CELU ( "Celularity" or the "Company" ) , a regenerative and cellular medicine company, today announced that it terminated the employment of its Chief Financial Officer ( "CFO" ) , David Beers, effective immediately.

FLORHAM PARK, N.J., May 30, 2025 ( GLOBE NEWSWIRE ) -- Celularity Inc. ( Nasdaq: CELU ) ( "Celularity" or the "Company" ) , a cellular and regenerative medicine company, today announced that on May 28, 2025, Nasdaq notified the Company that it did not timely file its Quarterly Report on Form ...

Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year. Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year.

FLORHAM PARK, N.J., April 25, 2025 ( GLOBE NEWSWIRE ) -- Celularity Inc. ( Nasdaq: CELU ) ( "Celularity" or the "Company" ) , a cellular and regenerative medicine company, today announced that Nasdaq has notified the Company that it has not paid certain fees required by Listing Rule 5250 ( f ) ...